

**NIH Consensus Development Conference:
Management of Hepatitis B
October 20–22, 2008**

Preliminary Agenda

Monday, October 20, 2008

- 8:30 a.m. Opening Remarks
Griffin P. Rodgers, M.D. (pending confirmation)
Director
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
- 8:40 a.m. Charge to the Panel
Barnett S. Kramer, M.D., M.P.H.
Director
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
- 8:50 a.m. Conference Overview and Panel Activities
Michael F. Sorrell, M.D.
Panel and Conference Chairperson
Robert L. Grissom Professor of Medicine
Section of Gastroenterology and Hepatology
University of Nebraska Medical Center

I. What Is the Current Burden of Hepatitis B?

- 9:00 a.m. Hepatitis B Virus and the Disease It Causes
T. Jake Liang, M.D.
Chief, Liver Diseases Branch
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
- 9:20 a.m. Evaluation of the Patient With Hepatitis B
Eugene Schiff, M.D., M.A.C.P., F.R.C.P., M.A.C.G.
Chief, Division of Hepatology
Director, Center for Liver Diseases
University of Miami School of Medicine
Miami, FL

Monday, October 20, 2008 (continued)

I. What Is the Current Burden of Hepatitis B? (continued)

- 9:40 a.m. Epidemiology of Hepatitis B
W. Ray Kim, M.D.
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
- 10:00 a.m. Recommendations for Identification and Public Health Management
of Persons With Chronic Hepatitis B Virus Infection
Cindy Weinbaum, M.D., M.P.H.
Team Leader, Prevention Branch
Division of Viral Hepatitis
Centers for Disease Control and Prevention
Atlanta, GA
- 10:20 a.m. **Discussion**

II. What Is the Natural History of Hepatitis B?

- 11:00 a.m. Introduction to the Natural History of Hepatitis B
Brian J. McMahon, M.D.
Scientific Program and Clinical Director
Liver Disease and Hepatitis Program
Alaska Native Medical Center
Anchorage, AK
- 11:20 a.m. Hepatitis B and Liver Cancer
Adrian M. Di Bisceglie, M.D., F.A.C.P.
Chief of Hepatology, Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
Saint Louis, MO
- 11:40 a.m. Liver Biopsy Findings in Chronic Hepatitis B
David E. Kleiner, M.D., Ph.D.
Chief, Postmortem Pathology and Director of Clinical Operations
Center for Cancer Research
Laboratory of Pathology
National Cancer Institute
National Institutes of Health
- 12:00 p.m. **Lunch**
Panel Executive Session

Monday, October 20, 2008 (continued)

II. What Is the Natural History of Hepatitis B? (continued)

- 1:00 p.m. HBV DNA Levels and Outcomes of Chronic Hepatitis B
Chien-Jen Chen, Sc.D., M.P.H.
Minister, Taiwan National Science Council
Executive Yuan
Republic of China
Taipei, Taiwan
- 1:20 p.m. Evidence-Based Practice Center Presentation I
EPC Speaker
- 1:40 p.m. **Discussion**

III. What Are the Benefits and Risks of the Current Therapeutic Options for Hepatitis B?

- 2:30 p.m. Overview of the Risks and Benefits of Current Therapeutic Options for Hepatitis B
E. Jenny Heathcote, M.D., F.R.C.P.C.
Head, Division of Patient Based Clinical Research
Toronto Western Research Institute
Toronto, Ontario
Canada
- 2:50 p.m. Benefits and Risks of Interferon Therapy for Hepatitis B
Robert P. Perrillo, M.D.
Associate Director, Hepatology Division
Program Director, Transplant Hepatology
Baylor University Medical Center
Dallas, TX
- 3:10 p.m. Benefits and Risks of Nucleoside Analogues for Hepatitis B
Jules L. Dienstag, M.D.
Dean for Medical Education
Carl W. Walter Professor of Medicine
Harvard Medical School
Boston, MA

Monday, October 20, 2008 (continued)

III. What Are the Benefits and Risks of the Current Therapeutic Options for Hepatitis B?

- 3:30 p.m. Benefits and Risks of Combination Therapy for Hepatitis B
Norah A. Terrault, M.D., M.P.H.
Assistant Professor, Medicine and Gastroenterology
UCSF School of Medicine
San Francisco, CA
- 3:50 p.m. Evidence-Based Practice Center Presentation II
EPC Speaker
- 4:10 p.m. **Discussion**
- 5:00 p.m. **Adjournment**

Tuesday, October 21, 2008

IV. Which Persons With Hepatitis B Should Be Treated?

- 8:30 a.m. Indications for Therapy in Hepatitis B
Anna S. K. Lok, M.D., M.R.C.P.
Director of Clinical Hepatology
University of Michigan Medical School
Ann Arbor, MI
- 8:50 a.m. HIV/HBV Coinfection
Chloe L. Thio, M.D.
Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins School of Medicine
Baltimore, MD
- 9:10 a.m. Special Populations and Hepatitis B
Marion G. Peters, M.D.
John V. Carbone, M.D. Endowed Chair in Medicine
Director of Hepatology Research
UCSF School of Medicine
San Francisco, CA

Tuesday, October 21, 2008 (continued)

IV. Which Persons With Hepatitis B Should Be Treated? (continued)

9:30 a.m. Prevention of Reactivation of Hepatitis B
Jay H. Hoofnagle, M.D.
Director, Liver Disease Research Branch
Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

9:50 a.m. Evidence-Based Practice Center Presentation III
EPC Speaker

10:10 a.m. **Discussion**

5. What Measures Are Appropriate To Monitor Therapy of Hepatitis B and Assess Outcomes?

11:00 a.m. Monitoring During and After Antiviral Therapy for Hepatitis B
Ray Chung, M.D.
Assistant Professor of Medicine
Harvard Medical School
Medical Director, Liver Transplant Program
Massachusetts General Hospital
Boston, MA

11:20 a.m. Antiviral Resistance and Hepatitis B Therapy
Mark G. Ghany, M.D.
Investigator, Liver Diseases Branch
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

11:40 a.m. Side Effects of Long-Term Antiviral Therapy for Hepatitis B
Robert J. Fontana, M.D.
Associate Professor, Department of Internal Medicine
Medical Director of Liver Transplantation
University of Michigan Medical School
Ann Arbor, MI

12:00 p.m. **Discussion**

12:30 p.m. **Adjournment**

Wednesday, October 22, 2008

9:00 a.m. **Presentation of the Draft Consensus Statement**

9:30 a.m. **Public Discussion**

11:00 a.m. **Panel Meets in Executive Session**

2:00 p.m. **Press Conference**

3:00 p.m. **Adjournment**